Bioventix AI Stock Analysis
Want to see GB:BVXP full AI Analyst Report?
Bioventix (BVXP) AI Stock Analysis
Bioventix
(LSE:BVXP)
The overall score of 81 is driven primarily by the company's outstanding financial health, characterized by best-in-class margins, a debt-free balance sheet, and flawless cash conversion. A very attractive 7.5% dividend yield and reasonable P/E ratio further support the valuation. The main risk is the recent stall in revenue growth, which prevents a higher score. Technicals confirm a strong uptrend, though near-term momentum indicators suggest caution.
Bioventix (BVXP) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 102.93M
- Dividend Yield
- 7.61%
- Average Volume (3M)
- 15.85K
- Price to Earnings (P/E)
- 13.6
- Beta (1Y)
- 0.59
- Revenue Growth
- -1.10%
- EPS Growth
- 0.32%
- Country
- UK
- Employees
- 12
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Bioventix Business Overview & Revenue Model
Company Description
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical area...
Bioventix Financial Statement Overview
Summary
Exceptional profitability with 90%+ gross margins and a fortress balance sheet with virtually no debt. Cash conversion exceeds 99%. The score is tempered by recent revenue stagnation and a slight -3.6% annual decline.
Income Statement
78PositiveBalance Sheet
95Very PositiveCash Flow
88Very Positive| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.97M | 12.97M | 13.12M | 13.61M | 12.82M | 11.72M |
| Gross Profit | 11.81M | 11.81M | 11.92M | 12.68M | 11.86M | 10.87M |
| EBITDA | 9.79M | 9.79M | 10.17M | 10.74M | 10.20M | 9.42M |
| Net Income | 7.61M | 7.61M | 7.58M | 8.10M | 8.37M | 7.67M |
Balance Sheet | ||||||
| Total Assets | 12.83M | 12.83M | 12.86M | 13.73M | 13.28M | 13.12M |
| Cash, Cash Equivalents and Short-Term Investments | 5.26M | 5.26M | 5.08M | 6.00M | 5.72M | 6.13M |
| Total Debt | 10.97K | 10.97K | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.41M | 1.41M | 1.31M | 1.73M | 1.22M | 1.30M |
| Stockholders Equity | 11.42M | 11.42M | 11.55M | 12.00M | 12.06M | 11.82M |
Cash Flow | ||||||
| Free Cash Flow | 8.02M | 8.02M | 7.01M | 8.33M | 7.89M | 7.55M |
| Operating Cash Flow | 8.09M | 8.09M | 7.03M | 8.34M | 7.90M | 7.56M |
| Investing Cash Flow | -71.60K | -71.60K | 173.16K | 186.06K | 90.51K | -11.76K |
| Financing Cash Flow | -7.84M | -7.84M | -8.12M | -8.25M | -8.30M | -7.92M |
Bioventix Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BVXP, the sentiment is Positive. The current price of 1970.00 is above the 20-day moving average (MA) of 1919.80, above the 50-day MA of 1716.60, and above the 200-day MA of 1592.90, indicating a bullish trend. The MACD of 67.40 indicates Positive momentum. The RSI at 65.47 is Neutral, neither overbought nor oversold. The STOCH value of 43.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:BVXP.
Bioventix Peers Comparison
Overall Rating
GB:BVXP81Outperform
GB:4BB52Neutral
GB:APTA46Neutral
GB:AVCT40Underperform
GB:FAB40Underperform
GB:OBD40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | GBP 102.93M | 13.59 | 67.81% | 7.61% | -1.10% | 0.32% | |
| 52Neutral | GBP 100.70M | -4.53 | -316.73% | ― | -56.10% | -16.77% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | GBP 12.66M | -12.17 | -46.61% | ― | 28.35% | 57.14% | |
| 40Underperform | GBP 287.20M | -6.47 | -1293.07% | ― | ― | ― | |
| 40Underperform | GBP 5.32M | -4.29 | -97.87% | ― | 7.38% | 44.13% | |
| 40Underperform | GBP 15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:BVXP | Bioventix plc | 1970.00 | -17.97 | -0.90% | |
| GB:AVCT | Avacta Group plc | 59.00 | -22.00 | -27.16% | |
| GB:OBD | Oxford BioDynamics | 0.12 | -0.17 | -58.93% | |
| GB:FAB | Fusion Antibodies Plc | 4.25 | -8.00 | -65.31% | |
| GB:4BB | 4basebio UK Societas | 525.00 | -187.50 | -26.32% | |
| GB:APTA | Aptamer Group Plc | 0.36 | -0.57 | -60.75% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026
